NCT05160012

Brief Summary

As part of a roll out of new payment model for physicians based on hypertension control, the investigators will evaluate a monthly peer comparison message to Primary Care Providers at Penn Medicine Lancaster to see whether provider engagement with patients' overall hypertension management increases, as measured by new or increasing doses of anti-hypertensive medications.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
93

participants targeted

Target at P25-P50 for not_applicable hypertension

Timeline
Completed

Started Apr 2022

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 16, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

April 5, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 6, 2022

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

December 4, 2025

Status Verified

December 1, 2025

Enrollment Period

6 months

First QC Date

November 9, 2021

Last Update Submit

December 3, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in new hypertensive medication prescriptions or an increased dose of hypertensive medication

    Change in new hypertensive medication prescriptions or an increased dose of hypertensive medication from baseline to the follow up period, as measured by the proportion of patients with a new prescription or dose placed for hypertensive medications in the electronic health record (EHR) from baseline to follow-up

    6 months

Secondary Outcomes (1)

  • Change in hypertension control percentage

    6 months

Study Arms (2)

Control

NO INTERVENTION

This group will not receive peer comparison messages and will continue with usual care.

Intervention

EXPERIMENTAL

This group will receive peer comparison messages.

Behavioral: Peer Comparison Message

Interventions

In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in: 1. If HTN control rate \<50th percentile, PCP is told they are below median 2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer 3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer

Intervention

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Primary Care Providers who have at =\>30 patients hypertension as determined by the HTN quality metric
  • Patients aged 18-85 with hypertension in their encounter diagnosis within the last 2 years (office visits, ED/Urgent Care, Hospital, Hospital Encounter, and Prenatal Visit)
  • Patients will be counted in the denominator of the quality metric if they have both systolic and diastolic BP measures from an encounter with their PCP department within the last year (including office visits, well child, prenatal visit, consult visit, confidential, e-visit, nursing only, home/offsite visit, and telemedicine) that is \>140 for systolic BP and \>90 diastolic BP

You may not qualify if:

  • Primary Care Providers includes providers with \<30 patients in the HTN quality metric
  • Patients will be excluded if they are 66 and older with a frailty diagnosis and those with an advanced illness diagnosis within the past year; 81 and older with frailty diagnosis within the past year
  • It also excludes patients with end stage renal disease (indicated by evaluation of the GFR, diagnosis of end stage renal disease in last year, dialysis received in last year, or renal transplant) and patients with a pregnancy diagnosis in the last 9 months
  • It also excludes patients with an end of life indicator (comfort care encounter in last year, comfort care noted in problem list in last year, and comfort care/palliative care procedures in last year)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lancaster General Hospital

Lancaster, Pennsylvania, 17602, United States

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Shivan Mehta, MD,MBA,MSHP

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 9, 2021

First Posted

December 16, 2021

Study Start

April 5, 2022

Primary Completion

October 6, 2022

Study Completion

April 1, 2026

Last Updated

December 4, 2025

Record last verified: 2025-12

Locations